BenevolentAI
poised for growth and success strengthened position enhances our leadership position in enabled drug discovery and enable us to independently pursue the clinical development of certain in house pipeline assets in core therapeutic areas out license multiple assets over the next years to strengthen our balance sheet and drive long term value creation increase the size of our pipeline with a healthy balance of new in class and best in class assets with stage drug candidates every year sign new collaboration agreements with companies to to leverage our disease agnostic capabilities into therapeutic indications outside our focus areas to generate incremental revenue maintain our leading position in target through increased investment in our technology capabilities build out our technology metrics to exemplify the differentiation of our approach | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
73 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Presentation
October 2022
poised for growth and success strengthened position enhances our leadership position in enabled drug discovery and enable us to independently pursue the clinical development of certain in house pipeline assets in core therapeutic areas out license multiple assets over the next years to strengthen our balance sheet and drive long term value creation increase the size of our pipeline with a healthy balance of new in class and best in class assets with stage drug candidates every year sign new collaboration agreements with companies to to leverage our disease agnostic capabilities into therapeutic indications outside our focus areas to generate incremental revenue maintain our leading position in target through increased investment in our technology capabilities build out our technology metrics to exemplify the differentiation of our approach | BenevolentAI
Related slides by other companies
Dare Bioscience
Investor Presentation
February 2023
intravaginal ring technology highlights the vaginal route of drug administration our technology design features vaginal drug delivery offers many potential advantages due to large surface area dense network of blood vessels and high elasticity due to presence of smooth muscle fibers recognized advantages include comparable ease of administration and ability to bypass hepatic first pass metabolism sustained drug delivery variable dosing and duration solid ethylene vinyl acetate polymer matrix that can contain and release one or several active drugs no need for membrane or reservoir to contain active drug or control the release | Dare Bioscience
Melrose
Results
September 2020
automotive advantaged long term technology position | Melrose
AbCellera
Investor Conference
September 2021
revitalize drug discovery with modern technologies on more a | AbCellera
Absci
Investor Presentation
July 2023
technology validated through industry leading collaborations | Absci
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io